- Login
- Register & Subscribe
- Language: EN FR DE
Finance, Grants, Deals
Auris Medical secures CHF 47.1 million
Tuesday 16 April 2013
Auris Medical AG of Switzerland has secured CHF 47.1 million (38.7 million euro) in a Series C funding round led by Sofinnova Ventures of the US and Sofinnova Partners of Paris, France. The funding will support two inner ear therapies.
Location
Switzerland
Series A money for GenSight Biologics
Monday 8 April 2013
GenSight Biologics, a privately-owned French company, has raised €32 million in a Series A round from a group of venture capital funds to develop a gene replacement therapy for Leber’s hereditary optic neuropathy (LHON), a serious eye disorder.
Location
France
AstraZeneca acquires AlphaCore Pharma
Wednesday 3 April 2013
AstraZeneca Plc said that its MedImmune biologics unit has acquired AlphaCore Pharma Inc of the US which has a product in development, ACP-501, for the acute treatment of atherosclerosis, a hardening of the artery walls following a build-up of cholesterol.
Location
United States
Evolva raises CHF 31.3 million
Wednesday 27 March 2013
The Swiss synthetic biology company, Evolva Holding SA, has raised CHF 31.3 million (€25.7 million) in a share placement with existing and new investors in order to support its portfolio of nutritional and pharmaceutical products.
Location
Switzerland
Shire to acquire SARcode Bioscience Inc
Tuesday 26 March 2013
Shire Plc has bolstered its portfolio for the second time in two weeks with plans to acquire SARcode Bioscience Inc of the US which has a late-stage product for treating the symptoms of dry eye disease. The deal includes an upfront payment of $160 million.
Location
United States
£25 million for new UK healthcare company
Monday 25 March 2013
A new UK company, Infirst Healthcare, that is developing new versions of existing cough, cold and pain medicines has raised £25 million from Invesco Asset Management Ltd to launch its first product in Europe and to complete development of a second.
Location
United Kingdom
Who is ahead, Pharma or venture capital?
Saturday 16 March 2013
Are venture capitalists getting better terms from their portfolio sales to Big Pharma or is it the other way around? In a lively discussion about the state of the biotech industry, panelists from the world of venture capital and industry said the relationship between the two parties can be prickly at times. But both sides need one another. The discussion took place at the annual Bio-Spring meeting in Barcelona Spain on 11 March 2013.
Location
Spain
Mesoblast raises A$170 million for cell therapies
Thursday 14 March 2013
Mesoblast Ltd of Australia has raised A$170 million (€136.3 million) in a private placement of its shares with existing and new investors including M&G Investment Management and Capital Research. The monies will fund the company’s cell therapies.
Location
Australia
Shire acquires Premacure of Sweden
Wednesday 13 March 2013
Shire Plc has expanded its portfolio of potential medicines for rare diseases with the acquisition of the privately-held Swedish company, Premacure AB, of Uppsala. The key asset is a protein replacement therapy for the prevention of retinopathy of prematurity.
Location
United States
UK start-up to advance AD compound
Friday 8 March 2013
A new UK start-up based on technology from King’s College London has received funding from Advent Venture Partners. CoCo Therapeutics Ltd will progress an approach for Alzheimer’s disease that involves the retinoic acid receptor, RAR-alpha.
Location
United Kingdom
Select a News Category
Recent Appointments
Steffen Thirstrup joins NDA Group
Monday June 10 2013
Tarquin Bennett-Coles joins Odgers Berndtson
Monday June 10 2013
Sandy Eisen becomes non-executive director at Phosphate Therapeutics
Thursday June 6 2013
Eric-Paul Paques to chair Grünenthal
Thursday June 6 2013
Charles DeCarli joins advisory board at DiaGenic
Thursday June 6 2013